GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Degree of Financial Leverage

Cleo Diagnostics (ASX:COV) Degree of Financial Leverage : 0.00 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Cleo Diagnostics's Degree of Financial Leverage for the quarter that ended in Jun. 2024 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Cleo Diagnostics's Degree of Financial Leverage or its related term are showing as below:

ASX:COV's Degree of Financial Leverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.97
* Ranked among companies with meaningful Degree of Financial Leverage only.

Cleo Diagnostics Degree of Financial Leverage Historical Data

The historical data trend for Cleo Diagnostics's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Degree of Financial Leverage Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24
Degree of Financial Leverage
- -

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Degree of Financial Leverage - - - -

Competitive Comparison of Cleo Diagnostics's Degree of Financial Leverage

For the Medical Devices subindustry, Cleo Diagnostics's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cleo Diagnostics's Degree of Financial Leverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Degree of Financial Leverage falls into.



Cleo Diagnostics Degree of Financial Leverage Calculation

Cleo Diagnostics's Degree of Financial Leverage for the quarter that ended in Jun. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.032 (Jun. 2024) / -0.066 (Jun. 2023) - 1 )/( -3.733 (Jun. 2024) / -1.619 (Jun. 2023) - 1 )
=-0.5152/1.3057
=-0.39***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Cleo Diagnostics  (ASX:COV) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Cleo Diagnostics Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics Headlines

No Headlines